Gary E. Gallick

17.8k total citations · 3 hit papers
202 papers, 13.7k citations indexed

About

Gary E. Gallick is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gary E. Gallick has authored 202 papers receiving a total of 13.7k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Molecular Biology, 100 papers in Oncology and 38 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gary E. Gallick's work include PI3K/AKT/mTOR signaling in cancer (25 papers), Prostate Cancer Treatment and Research (25 papers) and Bone health and treatments (22 papers). Gary E. Gallick is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (25 papers), Prostate Cancer Treatment and Research (25 papers) and Bone health and treatments (22 papers). Gary E. Gallick collaborates with scholars based in United States, Spain and Taiwan. Gary E. Gallick's co-authors include Nila U. Parikh, Lee M. Ellis, Justin M. Summy, James L. Abbruzzese, Wenbiao Liu, Douglas B. Evans, Huamin Wang, Serk In Park, Ami N. Shah and David J. McConkey and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Gary E. Gallick

202 papers receiving 13.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

2009 729 citations Thiruvengadam Arumugam, Vijaya Ramachandran et al. Cancer Research profile →
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571

2002 529 citations Ji Yuan Wu, Gary E. Gallick et al. profile →
Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

2009 527 citations James L. Abbruzzese, Gary E. Gallick et al. Cancer Research profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Gary E. Gallick	7.7k	6.0k	2.9k	2.0k	1.3k	202	13.7k
Robert B. Dickson	8.9k 1.2×	5.9k 1.0×	3.6k 1.2×	871 0.4×	1.7k 1.3×	221	16.1k
Atanasio Pandiella	6.6k 0.9×	4.9k 0.8×	1.5k 0.5×	1.2k 0.6×	771 0.6×	284	11.6k
Ivan Bièche	11.1k 1.4×	5.9k 1.0×	5.7k 2.0×	2.6k 1.3×	1.5k 1.1×	497	20.2k
Dean G. Tang	8.6k 1.1×	5.3k 0.9×	4.5k 1.6×	2.5k 1.3×	1.1k 0.8×	172	14.4k
Menashe Bar‐Eli	6.9k 0.9×	4.2k 0.7×	2.6k 0.9×	1.0k 0.5×	940 0.7×	186	12.0k
Evelyn Flynn	6.8k 0.9×	2.5k 0.4×	3.1k 1.1×	1.1k 0.6×	886 0.7×	66	11.4k
Kenneth J. Hillan	9.0k 1.2×	4.2k 0.7×	3.0k 1.1×	2.5k 1.3×	1.0k 0.8×	57	14.6k
Daniel E. Johnson	8.4k 1.1×	4.3k 0.7×	2.3k 0.8×	1.5k 0.7×	1.5k 1.2×	133	13.6k
Raffaella Giavazzi	6.2k 0.8×	4.0k 0.7×	3.4k 1.2×	944 0.5×	1.0k 0.8×	232	11.4k
Brett P. Monia	13.9k 1.8×	3.3k 0.6×	3.4k 1.2×	1.1k 0.6×	1.4k 1.0×	274	21.8k

Countries citing papers authored by Gary E. Gallick

Since Specialization

Citations

This map shows the geographic impact of Gary E. Gallick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary E. Gallick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary E. Gallick more than expected).

Fields of papers citing papers by Gary E. Gallick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary E. Gallick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary E. Gallick. The network helps show where Gary E. Gallick may publish in the future.

Co-authorship network of co-authors of Gary E. Gallick

This figure shows the co-authorship network connecting the top 25 collaborators of Gary E. Gallick. A scholar is included among the top collaborators of Gary E. Gallick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary E. Gallick. Gary E. Gallick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pan, Tianhong, Kelsea M. Hubka, Jian H. Song, et al.. (2020). Cabozantinib Reverses Renal Cell Carcinoma–mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo. Molecular Cancer Therapeutics. 19(6). 1266–1278. 11 indexed citations

Yu‐Lee, Li‐Yuan, Guoyu Yu, Yu‐Chen Lee, et al.. (2018). Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII–p38MAPK–pS249/T252RB Pathway. Cancer Research. 78(11). 2911–2924. 126 indexed citations

Yu, Guoyu, Chien-Jui Cheng, Song-Chang Lin, et al.. (2018). Organelle-Derived Acetyl-CoA Promotes Prostate Cancer Cell Survival, Migration, and Metastasis via Activation of Calmodulin Kinase II. Cancer Research. 78(10). 2490–2502. 30 indexed citations

Parseghian, Christine M., Nila U. Parikh, Ji Yuan Wu, et al.. (2017). Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research. 23(15). 4146–4154. 47 indexed citations

Li, Chunlai, Shouyu Wang, Zhen Xing, et al.. (2017). A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis. Nature Cell Biology. 19(2). 106–119. 246 indexed citations

Varkaris, Andreas, Paul G. Corn, Nila U. Parikh, et al.. (2015). Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clinical Cancer Research. 22(1). 107–121. 37 indexed citations

Lee, Yu-Chen, Song-Chang Lin, Guoyu Yu, et al.. (2015). Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Research. 75(22). 4949–4959. 36 indexed citations

Vishwamitra, Deeksha, Choladda V. Curry, Serhan Alkan, et al.. (2015). The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK+ T-cell lymphoma. Molecular Cancer. 14(1). 22 indexed citations

Yu, Guoyu, Yu-Chen Lee, Chien-Jui Cheng, et al.. (2014). RSK Promotes Prostate Cancer Progression in Bone through ING3, CKAP2, and PTK6-Mediated Cell Survival. Molecular Cancer Research. 13(2). 348–357. 42 indexed citations

10.

Lee, Yu-Chen, Mehmet Asım Bilen, Guoyu Yu, et al.. (2013). Inhibition of Cell Adhesion by a Cadherin-11 Antibody Thwarts Bone Metastasis. Molecular Cancer Research. 11(11). 1401–1411. 35 indexed citations

11.

Bartley, Angela N., Nila U. Parikh, Chiu‐Hsieh Hsu, et al.. (2013). Colorectal Adenoma Stem-like Cell Populations: Associations with Adenoma Characteristics and Metachronous Colorectal Neoplasia. Cancer Prevention Research. 6(11). 1162–1170. 10 indexed citations

12.

Mao, Muling, Feng Tian, John M. Mariadason, et al.. (2012). Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. Clinical Cancer Research. 19(3). 657–667. 235 indexed citations

13.

Kim, Hye‐Sun, Hee Dong Han, Guillermo N. Armaiz-Peña, et al.. (2011). Functional Roles of Src and Fgr in Ovarian Carcinoma. Clinical Cancer Research. 17(7). 1713–1721. 62 indexed citations

14.

Lee, Yu-Chen, Chien-Jui Cheng, Mehmet Asım Bilen, et al.. (2011). BMP4 Promotes Prostate Tumor Growth in Bone through Osteogenesis. Cancer Research. 71(15). 5194–5203. 109 indexed citations

15.

Sen, Banibrata, Babita Saigal, Nila U. Parikh, Gary E. Gallick, & Faye M. Johnson. (2009). Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase–STAT3 Binding. Cancer Research. 69(5). 1958–1965. 100 indexed citations

16.

Kopetz, Scott, Donald P. Lesslie, Serk In Park, et al.. (2009). Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress. Cancer Research. 69(9). 3842–3849. 127 indexed citations

17.

Arumugam, Thiruvengadam, Vijaya Ramachandran, Keith F. Fournier, et al.. (2009). Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer. Cancer Research. 69(14). 5820–5828. 729 indexed citations breakdown →

18.

Kopetz, Scott, Ami N. Shah, & Gary E. Gallick. (2007). Src Continues Aging: Current and Future Clinical Directions. Clinical Cancer Research. 13(24). 7232–7236. 91 indexed citations

19.

Johnson, Faye M. & Gary E. Gallick. (2007). Src Family Nonreceptor Tyrosine Kinases as Molecular Targets for Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry. 7(6). 651–659. 80 indexed citations

20.

Han, Liz Y., Charles N. Landen, José G. Treviño, et al.. (2006). Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. Cancer Research. 66(17). 8633–8639. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact